Mediterranean Diet improves thrombosis biomarkers in high cardiovascular risk individuals: a randomized controlled trial

Short title: Mediterranean Diet and thrombosis mechanisms

Álvaro Hernáez,[1,2,*] Olga Castañer,[2,3] Anna Tresserra-Rimbau,[2,4] Xavier Pintó,[2,5] Montserrat Fitó,[2,3] Rosa Casas,[1,2] Miguel Ángel Martínez-González,[2,6,7] Dolores Corella,[2,8] Jordi Salas-Salvadó,[2,4] José Lapetra,[2,9] Enrique Gómez-Gracia,[2,10] Fernando Arós,[2,11] Miquel Fiol,[2,12] Lluis Serra-Majem,[2,13] Emilio Ros,[2,14], and Ramón Estruch[1,2,15]

[1]Cardiovascular Risk, Nutrition and Aging Research Unit, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain, [2]CIBER of Pathophysiology of Obesity and Nutrition (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain; [3]Cardiovascular Risk and Nutrition Research Group, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain; [4]Universitat Rovira i Virgili, Departament de Bioquímica i Biotecnologia, Unitat de Nutrició Humana. Hospital Universitari San Joan de Reus, Institut d'Investigació Pere Virgili (IISPV). Reus, Spain; [5]Lipids and Vascular Risk Unit, Internal Medicine, Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain; [6]Universidad de Navarra, Department of Preventive Medicine and Public Health, Pamplona, Spain; [7]Department of Nutrition, Harvard TH Chan School of Public Health, Boston, USA; [8]Department of Preventive Medicine, Universidad de Valencia, Valencia, Spain; [9]Department of Family Medicine, Research Unit, Distrito Sanitario Atención Primaria Sevilla, Sevilla, Spain; [10]Department of Preventive Medicine and Public Health, Universidad de Málaga, Málaga, Spain; [11]Department of Cardiology, Hospital Universitario de Álava, Vitoria, Spain; [12]Balearic Islands Health Research Institute, Hospital Son Espases, Palma de Mallorca, Spain; [13]Department of Clinical Sciences, Universidad de Las Palmas de Gran Canaria, Las Palmas, Spain; [14]Lipid Clinic, Endocrinology and Nutrition Service, IDIBAPS, Hospital Clínic, Barcelona, Spain; and [15]Internal Medicine Service, Hospital Clínic, Barcelona, Spain.

Word count (text): 3,438
Word count (abstract): 250
Figure/table count: 3 figures, 2 tables
Reference count: 38

KEY POINTS

- Following a Mediterranean diet improves thrombosis-related biomarkers
- Increased fruit, vegetable, nut, and fatty fish intakes and reduced processed meat consumptions are linked to these benefits

ABSTRACT

Following a Traditional Mediterranean diet (TMD) decreases cardiovascular risk. However, its anti-thrombotic effects are unexplored. We aimed to assess whether this diet improved platelet, coagulation, and fibrinolysis-related biomarkers in cardiovascular risk subjects. In 358 random PREDIMED Study volunteers (*Prevención con Dieta Mediterránea*), we assessed: 1) 1-year effects on thrombosis of TMD, enriched in virgin olive oil (TMD-VOO; *N*=120) or nuts (TMD-Nuts; *N*=119), versus a low-fat diet (*N*=119), and 2) associations between 1-year biomarker changes and increments in Mediterranean Diet adherence and key food group intakes. TMD-Nuts attenuated pro-thrombotic status (*P*=0.029), whilst TMD-VOO did it in a marginally significant way (*P*=0.076). TMD-VOO decreased HDL-bound α_1-antitrypsin levels (HDL pro-inflammatory/pro-thrombotic properties, *P*=0.034) and increased HDL platelet activating factor-acetylhydrolase activity (*P*=0.024). TMD-Nuts diminished non-esterified fatty acid levels (*P*=0.034). Only the low-fat diet was associated with increased platelet factor-4 concentrations (*P*=0.012) and thrombin activation (higher prothrombin factor$_{1+2}$ levels, *P*=0.003) versus baseline. 2-point TMD adherence increments were linked to 10.2 mg/dL fibrinogen decrements (*P*=0.011). 1-serving increments in vegetable intake were associated with platelet factor-4 concentration decreases (-9.21%, *P*=0.031). 1-portion increments in fruit and fatty fish consumption were linked to thrombin generation decrements (-7.72% –*P*=0.007– and -13.2% –*P*=0.046–, respectively). Increases in antithrombin levels were related to 1-serving increments in nut intake (+2.34%, *P*=0.033) and reductions in processed meat consumption (+2.00%, *P*=0.018). Finally, 1-portion decreases in processed meat intake were associated with reduced plasminogen activator inhibitor-1 levels (-10.4%, *P*=0.008). Summarizing, TMD and its typical food items were associated with improved thrombosis biomarkers in high cardiovascular risk individuals.

INTRODUCTION

Following a traditional Mediterranean Diet (TMD) prevents the development of cardiovascular outcomes[1,2]. The PREDIMED Study (*Prevención con Dieta Mediterránea)* was the largest intervention study performed so far to assess the effects of this dietary pattern on the primary prevention of major cardiovascular outcomes[1]. In its context, our group and others have reported that TMD effects on cardiovascular protection may be mediated by improvements in risk factors related to blood pressure, glucose metabolism, oxidative stress, and low-grade inflammation[3]. However, very scarce evidence related to TMD effects on other mechanisms such as thrombosis is available.

Thrombosis consists of the formation of a clot to avoid blood loss in case of a vessel disruption, whose excessive activation is also linked to an increased risk of atherosclerotic outcomes[4]. Thrombus generation is based on the occurrence of four phenomena (apparition of an endothelial lesion, platelet activation and aggregation, activation of the coagulation cascade, and fibrinolysis) which, in turn, are constituted by a chain of intertwined biochemical responses[4]. Excessive levels of biomarkers related to these responses (or defective, in the case of fibrinolysis) are linked to an increased risk of suffering atherosclerotic events. This association has been reported for plasma biomarkers of endothelial damage (von Willebrand factor[5]), platelet aggregation (P-selectin[6], platelet factor-4[7]), activation of coagulation (fibrinogen[8], thrombin formation –directly proportional to the levels of prothrombin fragment 1+2–[9], antithrombin[10]), and fibrinolysis (plasminogen activator inhibitor-1 –PAI1–[11], D-dimer[12]). Other substances (such as non-esterified fatty acids and nitrite/nitrate levels) have also been shown to be involved in the development of cardiovascular diseases through their capacity to modulate endothelial stress and platelet activation[13,14]. Finally, novel functional biomarkers such as the antithrombotic capacity of high-density lipoproteins (HDLs) (based on the interrelation between low-grade

inflammation –in which HDLs are involved– and thrombosis[8] and the activity of HDL-bound enzymes to hydrolyze pro-thrombotic signals such as the platelet activating factor[15] –the platelet activating factor acetylhydrolase, PAF-AH–) could also contribute to protecting against cardiovascular disease.

Although their link with atherosclerotic diseases is consistent, very few interventions with healthy dietary patterns have been associated with changes in thrombosis biomarkers. Following a TMD has only been associated with a decrease in P-selectin levels in high cardiovascular risk subjects in the context of the PREDIMED Trial[16]. Beyond our study, a cross-sectional study reported an inverse association between adherence to a Mediterranean-like diet and platelet levels[17]. Other small-scale prospective analysis with 21 young, healthy male volunteers assessed the impact of a TMD-like diet for 90 days on this process, and reported that this dietary pattern was associated with lower fibrinogen levels and a moderation of the coagulation response[18]. However, no extensive analysis of the long-term TMD effects on thrombosis mechanisms has been performed to date in a large-scale intervention trial.

Our main aim was to assess whether a 1-year intervention with TMD improved a comprehensive set of endothelial stress, platelet, coagulation, and fibrinolysis-related biomarkers in high cardiovascular risk subjects. Our secondary aims were to determine whether there were associations between 1-year changes in thrombosis biomarkers and: 1) increments in Mediterranean Diet adherence score values (dose-response compliance analysis), and 2) differences in the consumption of key food group whose intake was modified in the TMD intervention (virgin olive oil, nuts, fruits, vegetables, legumes, fish, processed meat, and wine).

MATERIALS AND METHODS

Study population

Study subjects belonged to the PREDIMED Study (*Prevención con Dieta Mediterránea*). It was a large-scale, parallel, multicenter, randomized controlled trial assessing the long-term effects of following a TMD on the prevention of primary cardiovascular disease in a population at high cardiovascular risk[1]. Volunteers were randomly assigned to follow one of the three following intervention groups (in a 1:1:1 ratio): 1) a TMD supplemented with virgin olive oil (TMD-VOO); 2) a TMD supplemented with mixed nuts (TMD-Nuts); and 3) a low-fat control diet. Further details of inclusion and exclusion criteria and the dietary intervention are available in **Supplemental Methods**.

We selected a random subsample of 358 subjects (4.8% of the total PREDIMED population, belonging to Hospital Clinic and IMIM study sites, with biological samples at baseline and after 1 year of dietary intervention) for the present analyses. 120 volunteers were allocated to the TMD-VOO intervention group, 119 to the TMD-Nuts one, and 119 to the low-fat diet. In these individuals, age, sex and educational level data were gathered at baseline. At baseline and after 1 year of intervention, trained clinical personnel collected the following information: 1) body mass index, waist circumference, blood pressure, smoking, and medication use; 2) physical activity levels (using a validated Minnesota Leisure-Time Physical Activity Questionnaire; 3) adherence to a Mediterranean diet (the 14-item Mediterranean Diet adherence score[19], used as a continuous variable); and 4) intake of 137 food items in the previous year (using a validated food frequency questionnaire). From the information in the food frequency questionnaires, we calculated the intakes of key TMD food groups (**Supplemental Methods**). In addition, trained nurses collected plasma and serum samples, and stored at -80ºC upon use and to quantify the

levels of fasting glucose, total and HDL cholesterol, and triglycerides by automatized methods[1,20].

All participants provided written informed consent before joining the study. The trial protocol was approved by local institutional ethic committees, registered under the International Standard Randomized Controlled Trial Number ISRCTN35739639 (http://www.isrctn.com/ISRCTN35739639), and thoroughly described in previous publications[1,20].

Thrombosis biomarkers

We determined thrombosis biomarkers in biological samples collected at baseline and after 1 year of intervention. We used ELISA kits to quantify the levels of: fibrinogen (*Human Fibrinogen SimpleStep ELISA kit*, ref.: ab208036, abcam, UK), plasminogen activator inhibitor-1 (PAI1; *Human PAI1 SimpleStep ELISA kit (SERPINE1)*, ref.: ab184863, abcam, UK), platelet factor-4 (*PF4 (CXCL4) Human SimpleStep ELISA kit*, ref.:ab189573, abcam, UK), prothrombin fragment 1+2 (*Human F1+2 (prothrombin fragment 1+2) ELISA kit*, ref.: E-EL-H1793, Elabscience, USA), and von Willebrand factor (*Human von Willebrand factor SimpleStep ELISA kit*, ref.: ab223864, abcam, UK). We assessed the concentrations of antithrombin (*Antithrombin III*, ref.: SR-1102016, Spinreact, Spain) and D-dimer (*D-Dimer*, ref.: SR-1709231, Spinreact, Spain) by immunoturbidimetry, and of non-esterified fatty acids (*Non-Esterified Fatty Acids*, ref.: FA115, Randox, Spain) using a colorimetric technique in an ABX-Pentra 400 autoanalyzer (Horiba-ABX, France). We quantified nitrates + nitrites by means of a colorimetric kit (*Nitrate/Nitrite Colorimetric Assay Kit*, ref.: CAY-780001, Cayman Chemical, USA). All the previous analyses were performed in citrate plasma samples. In parallel, in apolipoprotein B-depleted plasma samples (specimen in which all lipoproteins but high-density lipoproteins –HDLs– were eliminated, prepared from citrate plasma samples[21]), we determined the levels of total

cholesterol by colorimetry (*Cholesterol Enzymatic-Colorimetry*, ref.: SR-41022, Spinreact, Spain) and of α1-antitrypsin (*a-1-antitrypsin*, ref.: SR-1102054, Spinreact, Spain) by immunoturbidimetry in an ABX-Pentra 400 autoanalyzer (Horiba-ABX, France). With these data, we calculated α1-antitrypsin/cholesterol ratios. We also determined in these samples the activity of the PAF-AH enzyme by a colorimetric kit (*PAF Acetylhydrolase Activity Assay Kit*, ref.: K765-1000, Cayman Chemical, USA). An extended explanation of the quality control and inter-assay coefficients of variation is available in **Supplemental Methods**.

Sample size

Since the only thrombosis-related parameter assessed in the PREDIMED Study was P-selectin, we assumed that the variability of this parameter would be similar to that in our variables. Thus, a sample size of 119 individuals per group (total sample size: *N*=357) allowed ≥80% power to detect a 10% change relative to the mean baseline value of P-selectin levels (7.65 ng/mL) between post-and pre-intervention values, and a 14% change relative to the mean baseline value (10.8 ng/mL) in the differences among the three diets, considering a 2-sided type I error of 0.05, a loss rate of 5%, and the standard deviation of the differences in P-selectin values in this intervention (SD=28.9 ng/mL)[16].

Statistical analyses

We first checked the distribution of continuous variables in normality plots and by the Shapiro-Wilk test. We assessed whether there were differences in baseline values among the three intervention groups with one-way ANOVA tests for normally distributed continuous variables, Kruskal-Wallis tests for non-normally distributed continuous ones, and chi-squared tests (or exact Fisher tests when expected frequencies were <5) for categorical parameters.

We first calculated a continuous score reflecting the general activation of the thrombosis mechanisms at baseline and after 1-year of intervention. In biomarkers where high concentrations were associated with a more pro-thrombotic state (von Willebrand factor, platelet factor-4, fibrinogen, prothrombin fragment 1+2, D-dimer, PAI-1, non-esterified fatty acids, and α_1-antitrypsin in HDL), we assigned values from 1 to 5 to the volunteers located in increasing quintiles. On the contrary, in biomarkers where high levels were linked to a less pro-thrombotic state (antithrombin, nitrites+nitrates, and PAF-AH activity in HDL), we assigned values from 5 to 1 to the volunteers located in increasing quintiles. By summing these scores, we obtained a general pro-thrombotic score ranging from 11 (all biomarkers located in the least pro-thrombotic quintile) to 55 (all biomarkers located in the most pro-thrombotic quintile), in which higher scores indicated a higher pro-thrombotic state.

We analyzed differences between pre- and post-intervention values in every intervention by paired t tests in normally distributed variables and Wilcoxon signed rank tests in non-normally distributed parameters. We checked whether there were differences in the 1-year changes in thrombosis biomarkers (calculated by subtracting baseline to post-intervention values) among the three intervention groups by multivariate linear regression analyses.

We assessed whether there were relationships between 1-year changes by Pearson's correlation tests. Finally, we studied whether there were associations between 1-year changes in the Mediterranean diet adherence score or the intake of key food groups (virgin olive oil; mixed nuts; fruits; vegetables; legumes; fish; processed meat; eggs; and wine) and the 1-year changes in thrombosis biomarkers by additional multivariate linear regression analyses. Associations with 1-year increments in the intake of food servings were performed with percentage changes, calculated as follows: (1-year value – baseline value)/baseline value x100). All regression models were adjusted for: age, sex, study site, educational level, baseline value of the variable, fasting glucose levels, use of antidiabetic drugs (yes/no), cholesterol concentrations, use of cholesterol-lowering drugs (yes/no),

triglyceride values, use of triglyceride-lowering drugs (yes/no), systolic blood pressure, use of antihypertensive drugs (yes/no), use of antithrombotic drugs (yes/no), tobacco use (never/former/actual smoker), body mass index, waist circumference, leisure-time physical activity, and two propensity scores to correct for the theoretical deviations in the randomization process (calculated from 30 baseline variables)[1]. Models were plotted using the "lme" package in R Software[22].

We considered any two-sided *P*-value<0.05 as significant and performed statistical analyses with R software version 3.5.0[23].

Data sharing statement

Considering that we do not have the explicit written consent of the study volunteers to yield their deidentified data at the conclusion of the study, individual participant data cannot be shared. The study protocol is available in the main publication of the study[1] and in the study website (http://www.predimed.es/uploads/8/0/5/1/8051451/_1estr_protocol_olf.pdf), and a summary of the dietary intervention is also available in **Supplemental Methods**.

RESULTS

Study population

We found no significant differences in clinical variables at baseline among the individuals assigned to the three intervention groups (**Table 1**). Regarding the total PREDIMED Study population, there were 5.9% more women and 7% more antithrombotic drug users among our volunteers and they presented higher glucose (6 mg/dL), total cholesterol (4 mg/dL), and leisure-time physical activity levels (22 METs·min/d) (*P*<0.05) (**Supplemental Table 1**). Physical activity did not change throughout the study (*P*>0.05), and volunteers'

compliance to the dietary intervention was correct according to the Mediterranean diet adherence score (we observed a 1.26 and 1.41-point increment in score values after 1 year of intervention in the TMD-VOO and TMD-Nuts interventions, respectively; $P<0.001$ relative to baseline and the control intervention). TMD adherence increased in the TMD-VOO group due to increments in the intake of virgin olive oil, vegetables, legumes, total and fatty fish, white meat, and wine, and decrements in the consumption of red and processed meat (virgin olive oil, vegetable, legume, total and fatty fish intake changes were significant relative to the low-fat diet, $P<0.05$). In the TMD-Nuts group, TMD adherence increased because of increments in the consumption of nuts, virgin olive oil, fruits, legumes, and fatty fish and decreases in the intake of red and processed meats (nut, fatty fish, and processed meat consumption changes were significant relative to the control diet, $P<0.05$). Finally, low-fat diet compliance was observed as a reduction in the consumption of fats, based on a decrease of the intake of mixed nuts and the substitution of red for white meat (red meat consumption decreased while meat did not) and the substitution of fatty for non-fatty fish (total fish intake increased while fatty fish did not) ($P<0.05$) (**Supplemental Table 2**).

TMD interventions and thrombosis biomarkers

Overall pro-thrombotic status (measured as the thrombosis score) was attenuated by the TMD-Nuts intervention ($P=0.029$) and marginally moderated by the TMD-VOO one ($P=0.076$) in relation to the low-fat diet. TMD-VOO decreased the levels of α_1-antitrypsin ($P=0.034$) and increased the platelet activating factor-acetylhydrolase activity in HDLs ($P=0.024$) relative to the control intervention. TMD-Nuts diminished the concentrations of non-esterified fatty acids versus the low-fat diet ($P=0.034$). Great increases in TMD compliance (measured as 2-point increments in the TMD adherence score) were associated with 10.2 mg/dL decreases in fibrinogen levels ($P=0.011$) (**Figure 1**).

Finally, when assessing post- vs. pre-intervention changes, only the low-fat diet was associated with increased platelet factor-4 concentrations (*P*=0.012) and thrombin activation (higher prothrombin factor$_{1+2}$ levels, *P*=0.003) (**Table 2**). Exact coefficients are available in **Supplemental Table 3**.

Associations between changes in food servings and thrombosis biomarkers

Regarding platelet-related biomarkers, 1-serving increases in vegetable intake (100 g/d) were associated with platelet factor-4 concentration decreases (-9.21%, *P*=0.031). In relation to coagulation-related parameters, 1-portion increments in fruit (100 g/d) and fatty fish (25 g/d) consumption were linked to thrombin generation decrements (-7.72% –*P*=0.007– and -13.2% –*P*=0.046–, respectively). In addition, 1-serving increments in nut intake (30 g/d) and reductions in processed meat consumption (25 g/d) were associated with increases in antithrombin levels (+2.34% –*P*=0.033– and +2.00% –*P*=0.018–, respectively). Regarding fibrinolysis-related biomarkers, 1-portion decreases in processed meat intake were associated with reduced PAI-1 levels (-10.4%, *P*=0.008). Finally, regarding other pro-thrombotic mechanisms, 1-serving decrements in the consumption of processed meat were linked to increments in the PAF-AH activity in HDLs and nitrite + nitrate levels in plasma (+6.10% –*P*=0.011– and +14.6% –*P*=0.027–, respectively) (**Figure 2**). Exact association coefficients are available in **Supplemental Table 4**.

Correlation analyses between 1-year changes in thrombosis biomarkers

There were significant, strong, positive associations among increments in platelet factor-4, thrombin activation, and PAI-1 levels (*rho*>0.59, $P<10^{-5}$). Regarding inflammation-related biomarkers, increases in fibrinogen levels were positively associated with increases in von Willebrand factor concentrations and α_1-antitrypsin levels in HDL (*rho*>0.15, $P<5\cdot10^{-4}$). Changes in HDL thrombosis-related properties were correlated as well, since increments

in α_1-antitrypsin levels were linked to decreases in PAF-AH activity in the lipoprotein (*rho*=0.23, $P<5\cdot10^{-4}$). Finally, increases in the levels of classical thrombosis biomarkers (platelet factor-4, thrombin activation, and PAI-1) and in HDL pro-inflammatory characteristics (its α_1-antitrypsin levels) correlated with decreases in antithrombin levels (rho<-0.20, $P<5\cdot10^{-4}$) (**Figure 3**).

DISCUSSION

Our results show that 1 year of intervention with TMD improves pro-thrombotic state in high cardiovascular risk individuals. To the best of our knowledge, this trial is the largest (*N*=358) and more comprehensive study on the effects of a healthy dietary pattern on the molecular mechanisms related to thrombosis.

Thrombosis, and particularly platelet and coagulation activation, seems to be deeply affected by inflammation and oxidative stress[24,25]. TMD is a lifestyle intervention known to improve both risk factors[3], and our data indicate that following this dietary pattern was also associated with an improvement in the overall pro-thrombotic response of high cardiovascular risk subjects. Several data from our study and others reinforce the hypothesis that TMD effects of thrombosis could be due to its capacity to moderate oxidative stress and low-grade inflammation. First, TMD adherence increments were particularly associated with fibrinogen decreases in our results. Fibrinogen is a pivotal molecule connecting hemostasis and inflammatory responses[26] and this fact emphasizes the possibility of an interlinked anti-inflammatory/antithrombotic TMD capacity. Second, TMD is a dietary pattern based in high intakes of food groups and nutrients able to decrease oxidative stress and low-grade inflammation responses (antioxidants[27], and polyunsaturated[28] and fiber-derived short-chain fatty acids[29]). Our results indicate that

increments in the consumption of some of the previous food groups (fruits, vegetables, nuts, and fatty fish) were linked to better levels of platelet factor-4, thrombin activation, and antithrombin (reflecting a lower activation of platelet function and the coagulation cascade). Finally, we have also observed that the decreases in inflammation-related biomarkers were also related to decrements in pro-thrombotic responses in our data. HDLs have been shown to be able to induce beneficial effects on some hemostatic mechanisms[30]. In this regard, the TMD-VOO intervention led to a particular decrease in α_1-antitrypsin levels and an increase in PAF-AH activity in HDL particles, two potential HDL antithrombotic properties. It is not the first time that we report that the TMD-VOO intervention promotes HDL functionality in the PREDIMED Study[21]. However, our data extend this protection to anti-inflammatory and anti-thrombotic HDL functions (also interconnected in our results). Antioxidant protection on HDL components of typical TMD food items could contribute to explaining an improved activity of the lipoprotein protective enzymes (due to a greater preservation of their non-oxidized structure)[31]. In addition, the capacity of this dietary pattern to decrease the levels of inflammation biomarkers in circulation may be related to a decrement in the concentrations of pro-inflammatory molecules bound to HDL particles[32].

We observed a decrease in non-esterified fatty acid levels after 1 year of TMD-Nuts intervention. Non-esterified fatty acids promote endothelial stress and platelet aggregation and, therefore, are considered an emergent pro-thrombotic risk factor in the cardiovascular risk states in which their levels are high (e.g., obesity, hypertriglyceridemia)[13]. The capacity of polyunsaturated fatty acids (whose intake was particularly increased in this group) to bind to GPR120 receptors in adipose tissue in order to decrease lipolysis[33,34] could be an explanation for this effect. In addition, TMD is a fiber-rich dietary pattern, whose intestinal metabolism leads to blood peaks of short-chain fatty acids (known to be able to bind other GPR family receptors with a similar anti-lipolytic effect[35]). Thus, a synergistic effect

between these two nutrients could also be expected in order to explain this particular decrease in the levels of these fatty acids in the TMD-Nuts intervention group.

Increments in processed meat consumption have been associated in our data with several deteriorations in the coagulation cascade (decreased antithrombin levels), fibrinolysis (PAI-1 concentrations), and other thrombosis biomarkers (nitrite + nitrate levels, PAF-AH activity in HDLs). These changes are plausible in the context of the cardiovascular risk associated with their intake. Consumption of processed meats been consistently associated with augmented incidences of atherosclerotic[36] and thromboembolic outcomes[37]. The pro-inflammatory state induced by processed meat components could contribute to explaining a possible pro-thrombotic response. Some of them (e.g., smoke flavors) may promote pro-inflammatory responses through the activation of aryl hydrocarbon receptor-mediated pathways[38]. In parallel, other substrates originated due to their digestion (hydrogen sulfide, other sulfur compounds, nitrosamines, ammonia, amino acid metabolism residues, etc.) may compromise intestinal integrity, increasing the colon permeability to pro-inflammatory bacterial endotoxins such as lipopolysaccharide[39].

Our study has several strengths. First, it presents a large sample size (*N*=358). Second, it is based on a randomized design with an active comparator (low-fat control diet) and a long-term duration (1 year). Last, it is the first analysis of the effects of a dietary pattern on a comprehensive, hypothesis-driven set of thrombosis-related biomarkers, performed after a strict laboratory quality control. However, it also presents limitations. First, our volunteers were elderly people at high cardiovascular risk and, therefore, the extrapolation of our conclusions to other populations is hindered. In addition, we report modest changes after the interventions. However, the PREDIMED trial is based on modest real-life dietary modifications and the control diet is already a well-known healthy dietary pattern (rich in fruits, vegetables, and legumes, and poor in fresh and processed meats).

In conclusion, 1 year of intervention with TMD improves pro-thrombotic state in high cardiovascular risk individuals. The TMD-VOO intervention improved HDL antithrombotic properties, the TMD-Nuts one enhanced the levels of non-esterified fatty acids, both TMD groups were not related to increments in the levels of platelet factor-4 and prothrombin activation (whilst the low-fat diet was), and increases in TMD adherences were dose-dependently related to decreases in fibrinogen levels. These effects seemed to be particularly based on increments in the intake of fruits, vegetables, nuts, and fatty fish, and decreases in processed meat consumption. As far as we know, this is the largest, most comprehensive, hypothesis-based analysis of the effects of a healthy dietary pattern on thrombosis mechanisms in high cardiovascular risk subjects. Our results support the improvement of thrombosis status after following a TMD. Further studies are needed to confirm whether these improvements mediate the reported cardioprotective benefits of this dietary pattern.

ACKNOWLEDGEMENTS

This work was supported by grants of Instituto de Salud Carlos III [OBN17PI02, PIE14/00045_INFLAMES, CB06/03/0019, CB06/03/0028, CD17/00122 (A.H.), and JR17/00022 (O.C.)], and Agència de Gestió d'Ajuts Universitaris i de Recerca (2017 SGR 222). The sponsors of this study are public/nonprofit organizations that support science in general and had no role in gathering, analyzing, or interpreting the data. CIBER de Fisiopatología de la Obesidad y Nutrición (CIBEROBN) is an initiative of the Instituto de Salud Carlos III, Madrid, Spain.

Authors wish to thank Daniel Muñoz-Aguayo, Gemma Blanchart, and Sònia Gaixas for their assistance in the development of the present research project.

AUTHORSHIP

Contribution: A.H. and M. Fitó designed the research; A.H., O.C. A.T.-R., X.P., and R.E were involved in funding search; X.P., M. Fitó, M.-Á. M.-G., D.C., J.S.-S., J.L., E.G.-G., F.A., M. Fiol, L.S.-M., E.R., and R.E. conducted the clinical trial and provided biological samples; A.H., O.C., M. Fitó, and R.C. developed the experimental part of the project; A.H. analyzed results and wrote the paper; O.C. A.T.-R., X.P., M. Fitó, R.C., M.-Á. M.-G., D.C., J.S.-S., J.L., E.G.-G., F.A., M. Fiol, L.S.-M., E.R., and R.E. revised the manuscript and approved its final version.

Conflict-of-interest disclosure: X.P. reports personal fees from Abbott, Esteve, Lacer, Rubio, and Sanofi outside the submitted work. J.S.-S. reports to be a board member and grants from Nut and Dried Fruit; personal fees from Aguas Font Vella Lanjarón, Danone S.A., and Instituto Danone; grants from Eroski Distributors; and non-financial support from Nuts for Life outside the submitted work. F.A. reports personal fees from Menarini and AstraZeneca outside the submitted work. E.R. reports personal fees and non-financial support from Merck, Sharp & Dohme; grants, personal fees, and non-financial support

from California Walnut Commission; grants and personal fees from Sanofi; personal fees and non-financial support from Ferrer International; and grants from Pfizer outside the submitted work. R.E. reports grants from Bicentury SA, Cerveza y Salud, Grand Fountaine, and Novartis SA; and personal fees from Brewers of Europe, FIVIN, Fundación Cerveza y Salud, Lilly Laboratories, and Wine and Culinary International Forum outside the submitted work. The rest of the authors have nothing to disclose.

Correspondence: Álvaro Hernáez, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), IDIBAPS Offices-Mallorca (Floor -1, PREDIMED Office), Carrer Mallorca 185, 08036, Barcelona, Spain; e-mail: alvaro.hernaez1@gmail.com.

REFERENCES

1. Estruch R, Ros E, Salas-Salvadó J, et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. *N. Engl. J. Med.* 2018;378(25):e34.
2. Martínez-González MA, Gea A, Ruiz-Canela M. The Mediterranean Diet and Cardiovascular Health. *Circ. Res.* 2019;124(5):779–798.
3. Martínez-González MA, Salas-Salvadó J, Estruch R, et al. Benefits of the Mediterranean Diet: Insights From the PREDIMED Study. *Prog. Cardiovasc. Dis.* 2015;58(1):50–60.
4. Gresele P, Momi S, Migliacci R. Endothelium, venous thromboembolism and ischaemic cardiovascular events. *Thromb. Haemost.* 2010;103(1):56–61.
5. Montalescot G, Philippe F, Ankri A, et al. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French Investigators of the ESSENCE Trial. *Circulation*. 1998;98(4):294–9.
6. Wassel CL, Berardi C, Pankow JS, et al. Soluble P-selectin predicts lower extremity peripheral artery disease incidence and change in the ankle brachial index: The Multi-Ethnic Study of Atherosclerosis (MESA). *Atherosclerosis*. 2015;239(2):405–411.
7. Altara R, Manca M, Brandao RD, et al. Emerging importance of chemokine receptor CXCR3 and its ligands in cardiovascular diseases. *Clin. Sci.* 2016;130(7):463–478.
8. Feinbloom D, Bauer KA. Assessment of hemostatic risk factors in predicting arterial thrombotic events. *Arterioscler. Thromb. Vasc. Biol.* 2005;25(10):2043–53.
9. Loeffen R, van Oerle R, Leers MPG, et al. Factor XIa and Thrombin Generation Are Elevated in Patients with Acute Coronary Syndrome and Predict Recurrent

Cardiovascular Events. *PLoS One*. 2016;11(7):e0158355.

10. Thompson SG, Fechtrup C, Squire E, et al. Antithrombin III and fibrinogen as predictors of cardiac events in patients with angina pectoris. *Arterioscler. Thromb. Vasc. Biol.* 1996;16(3):357–62.

11. Cortellaro M, Cofrancesco E, Boschetti C, et al. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients. A case-control study. The PLAT Group. *Arterioscler. Thromb. a J. Vasc. Biol.* 1993;13(10):1412–7.

12. Lowe GD, Rumley A. Use of fibrinogen and fibrin D-dimer in prediction of arterial thrombotic events. *Thromb. Haemost.* 1999;82(2):667–72.

13. Darvall KAL, Sam RC, Silverman SH, Bradbury AW, Adam DJ. Obesity and Thrombosis. *Eur. J. Vasc. Endovasc. Surg.* 2007;33(2):223–233.

14. Moshage H, Kok B, Huizenga JR, Jansen PL. Nitrite and nitrate determinations in plasma: a critical evaluation. *Clin. Chem.* 1995;41(6):.

15. Tellis CC, Tselepis AD. The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma. *Biochim. Biophys. Acta*. 2009;1791(5):327–38.

16. Casas R, Sacanella E, Urpí-Sardà M, et al. The effects of the mediterranean diet on biomarkers of vascular wall inflammation and plaque vulnerability in subjects with high risk for cardiovascular disease. A randomized trial. *PLoS One*. 2014;9(6):e100084.

17. Bonaccio M, Di Castelnuovo A, De Curtis A, et al. Adherence to the Mediterranean diet is associated with lower platelet and leukocyte counts: results from the Moli-sani study. *Blood*. 2014;123(19):3037–3044.

18. Mezzano D, Leighton F, Martínez C, et al. Complementary effects of Mediterranean diet and moderate red wine intake on haemostatic cardiovascular risk factors. *Eur.*

J. Clin. Nutr. 2001;55(6):444–51.

19. Schröder H, Fitó M, Estruch RR, et al. A short screener is valid for assessing Mediterranean diet adherence among older Spanish men and women. *J. Nutr.* 2011;141(6):1140–5.

20. Martínez-González MÁ, Corella D, Salas-Salvadó J, et al. Cohort profile: design and methods of the PREDIMED study. *Int. J. Epidemiol.* 2012;41(2):377–85.

21. Hernaez A, Castañer O, Elosua R, et al. Mediterranean Diet Improves High-Density Lipoprotein Function in High-Cardiovascular-Risk Individuals: A Randomized Controlled Trial. *Circulation*. 2017;135(7):633–643.

22. Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using **lme4**. *J. Stat. Softw.* 2015;67(1):1–48.

23. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2014;

24. Franco AT, Corken A, Ware J. Platelets at the interface of thrombosis, inflammation, and cancer. *Blood*. 2015;126(5):582–588.

25. Samad F, Ruf W. Inflammation, obesity, and thrombosis. *Blood*. 2013;122(20):3415–3422.

26. Luyendyk JP, Schoenecker JG, Flick MJ. The multifaceted role of fibrinogen in tissue injury and inflammation. *Blood*. 2019;133(6):511–520.

27. Hussain T, Tan B, Yin Y, et al. Oxidative Stress and Inflammation: What Polyphenols Can Do for Us? *Oxid. Med. Cell. Longev.* 2016;2016:7432797.

28. Marion-Letellier R, Savoye G, Ghosh S. Polyunsaturated fatty acids and inflammation. *IUBMB Life*. 2015;67(9):659–667.

29. Ohira H, Tsutsui W, Fujioka Y. Are Short Chain Fatty Acids in Gut Microbiota Defensive Players for Inflammation and Atherosclerosis? *J. Atheroscler. Thromb.* 2017;24(7):660–672.

30. van der Stoep M, Korporaal SJA, Van Eck M. High-density lipoprotein as a modulator of platelet and coagulation responses. *Cardiovasc. Res.* 2014;103(3):362–71.

31. Hernáez A, Farràs M, Fitó M. Olive oil phenolic compounds and high-density lipoprotein function. *Curr. Opin. Lipidol.* 2016;27(1):47–53.

32. Casas R, Sacanella E, Urpí-Sardà M, et al. Long-Term Immunomodulatory Effects of a Mediterranean Diet in Adults at High Risk of Cardiovascular Disease in the PREvención con DIeta MEDiterránea (PREDIMED) Randomized Controlled Trial. *J. Nutr.* 2016;146(9):1684–93.

33. Oh DY, Talukdar S, Bae EJ, et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. *Cell*. 2010;142(5):687–98.

34. Satapati S, Qian Y, Wu MS, et al. GPR120 suppresses adipose tissue lipolysis and synergizes with GPR40 in antidiabetic efficacy. *J. Lipid Res.* 2017;58(8):1561–1578.

35. den Besten G, van Eunen K, Groen AK, et al. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. *J. Lipid Res.* 2013;54(9):2325–40.

36. Bechthold A, Boeing H, Schwedhelm C, et al. Food groups and risk of coronary heart disease, stroke and heart failure: A systematic review and dose-response meta-analysis of prospective studies. *Crit. Rev. Food Sci. Nutr.* 2019;59(7):1071–1090.

37. Steffen LM, Folsom AR, Cushman M, Jacobs DR, Rosamond WD. Greater Fish, Fruit, and Vegetable Intakes Are Related to Lower Incidence of Venous Thromboembolism. *Circulation*. 2007;115(2):188–195.

38. Shmarakov IO. Retinoid-xenobiotic interactions: the Ying and the Yang. *Hepatobiliary Surg. Nutr.* 2015;4(4):243–67.

39. O'Keefe SJD. Diet, microorganisms and their metabolites, and colon cancer. *Nat. Rev. Gastroenterol. Hepatol.* 2016;13(12):691–706.

TABLES

Table 1. Description of the study population

	TMD-VOO (N=120)	TMD-Nuts (N=119)	Low-fat diet (N=119)	*P*-value
Sex (female) (*n*, %)	78 (65.0%)	75 (63.0%)	74 (62.2%)	0.898
Age (years)	67.3 (5.34)*	66.6 (5.79)	66.5 (6.35)	0.530
Educational level:				0.228
Primary or less (*n*, %)	95 (79.2%)	79 (66.4%)	81 (68.1%)	
Secondary (*n*, %)	15 (12.5%)	25 (21.0%)	21 (17.6%)	
Higher (*n*, %)	9 (7.50%)	14 (11.8%)	13 (10.9%)	
Non-available (*n*, %)	1 (0.83%)	1 (0.84%)	4 (3.36%)	
Glucose (mg/dL)	125 (39.9)	123 (46.8)	131 (46.5)	0.334
Use of glucose-lowering drugs (*n*, %)	41 (34.2%)	35 (29.4%)	44 (37.0%)	0.458
Total cholesterol (mg/dL)	213 (34.6)	214 (36.3)	207 (33.5)	0.298
HDL cholesterol (mg/dL)	53.4 (9.03)	51.2 (9.90)	51.0 (11.1)	0.138
LDL cholesterol (mg/dL)	134 (32.5)	137 (33.4)	131 (29.5)	0.406
Use of cholesterol-lowering drugs (*n*, %)	57 (47.5%)	44 (37.0%)	47 (39.5%)	0.225
Triglycerides (mg/dL)	114 [92.9; 156]†	109 [78.8; 156]	111 [84.5; 146]	0.669
Use of triglyceride-lowering drugs (*n*, %)	6 (5.00%)	7 (5.88%)	4 (3.36%)	0.650
Systolic blood pressure (mmHg)	154 (18.3)	155 (21.6)	153 (20.9)	0.668
Diastolic blood pressure (mmHg)	83.0 (10.5)	85.6 (11.3)	83.9 (8.90)	0.141
Use of antihypertensive drugs (*n*, %)	86 (71.7%)	79 (66.4%)	76 (63.9%)	0.423
Use of antithrombotic drugs (*n*, %)	19 (15.8%)	13 (10.9%)	14 (11.8%)	0.479
Tobacco use:				0.445

Never smoker (*n*, %)	83 (69.2%)	77 (64.7%)	69 (58.0%)	
Former smoker (*n*, %)	21 (17.5%)	27 (22.7%)	30 (25.2%)	
Actual smoker (*n*, %)	16 (13.3%)	15 (12.6%)	20 (16.8%)	
Body mass index (kg/m^2)	29.7 (3.37)	29.9 (3.50)	29.5 (3.34)	0.690
Waist circumference (cm)	101 (8.59)	101 (8.91)	99.9 (9.56)	0.623
Leisure-time physical activity (METs·min/d)	215 [103; 367]	177 [76.3; 332]	202 [59.4; 377]	0.385
Mediterranean diet adherence score	8.61 (1.68)	8.69 (1.85)	8.99 (1.64)	0.197

*: Mean (standard deviation)

†: Median [first quartile; third quartile]

HDL: high-density lipoprotein; *LDL*: low-density lipoprotein; *METs*: metabolic equivalents of task.

Table 2. Changes in thrombosis biomarkers throughout the 1-year intervention relative to baseline.

	Low-fat control diet (*N*=119)			TMD-VOO (*N*=120)			TMD-Nuts (*N*=119)		
Normally distributed variables (*paired t-tests*)									
	Post-int. value	Difference	*P*-value	Post-int. value	Difference	*P*-value	Post-int. value	Difference	*P*-value
Thrombosis score	30.3 (6.54)	0.50 (6.52)	0.434	30.2 (5.69)	0.057 (5.32)	0.913	29.3 (5.82)	-0.52 (5.87)	0.378
Von Willebrand factor (µg/mL)	31.2 (14.3)	-2.03 (14.8)	0.139	32.2 (14.5)	0.22 (13.6)	0.859	30.9 (12.9)	1.00 (11.9)	0.364
Fibrinogen (mg/dL)	275 (65.1)	7.40 (64.2)	0.211	277 (63.5)	-0.094 (68.0)	0.988	272 (62.1)	1.92 (57.8)	0.718
Antithrombin (mg/dL)	36.1 (4.44)	0.38 (4.14)	0.321	37.0 (4.37)	0.33 (3.19)	0.254	36.1 (5.29)	-0.15 (4.40)	0.718
PAI-1 (mg/dL)	3.68 (1.56)	0.080 (2.12)	0.683	3.60 (1.66)	0.009 (1.97)	0.962	3.68 (1.73)	0.098 (2.10)	0.619
D-dimer	1.12	0.057	0.360	1.13	0.063	0.378	1.25	0.089	0.251

(µg/mL)	(0.54)	(0.67)		(0.59)	(0.77)		(0.70)	(0.83)	
α1-antitrypsin in HDLs	2.09	0.073		1.98	0.028		2.00	-0.009	
(per mg of HDLc, no units)	(0.65)	(0.51)	0.130	(0.68)	(0.60)	0.615	(0.61)	(0.43)	0.825
PAF-AH activity in HDLs	1.00	-0.076		1.06	-0.036		1.05	-0.10	
(normalized units)	(0.35)	(0.33)	0.016	(0.38)	(0.38)	0.303	(0.36)	(0.42)	0.010
Non-esterified	0.53	-0.007		0.51	0.012		0.47	-0.036	
fatty acids (mmol/L)	(0.20)	(0.24)	0.736	(0.19)	(0.19)	0.495	(0.18)	(0.19)	0.038
Nitrites + nitrates	37.8	0.93		36.6	1.54		34.7	0.51	
(µM)	(33.8)	(40.1)	0.808	(24.8)	(24.2)	0.494	(24.3)	(27.9)	0.849
Non-normally distributed variables (*Wilcoxon signed rank tests*)									
	Pre-int. value	Post-int. value	*P*-value	Pre-int. value	Post-int. value	*P*-value	Pre-int. value	Post-int. value	*P*-value
Platelet factor-4	268	351		287	372		288	323	
(ng/mL)	[183; 431]	[211; 565]	0.012	[164; 498]	[202; 563]	0.168	[186; 486]	[205; 514]	0.901
Prothrombin fragment 1+2	261	319		246	312		275	289	
(pg/mL)	[149; 433]	[209; 538]	0.005	[162; 415]	[223; 487]	0.114	[165; 439]	[194; 443]	0.573

HDLc: HDL cholesterol, *PAF-AH*: platelet activating factor acetylhydrolase; *Pre-int.*: pre-intervention; *Post-int.*: post-intervention.

FIGURES

Figure 1. TMD effects on thrombosis biomarkers.



Effects of TMD-VOO (first forest plot of each panel) and TMD-Nuts interventions (second forest plot of each panel) (versus the low-fat control diet) and of 2-point increments in TMD adherence (third forest plot of each panel) on: thrombosis score (**A**), and levels of von Willebrand factor (**B**), platelet factor-4 (**C**), fibrinogen (**D**), prothrombin fragment 1+2 (**E**), antithrombin (**F**), plasminogen activator inhibitor-1 (**G**), D-dimer (**H**), α1-antitrypsin in HDLs (**I**), platelet activating factor acetylhydrolase activity in HDLs (**J**), non-esterified fatty acids (**K**), and nitrites + nitrates (**L**). Results are shown as adjusted coefficients with 95% confidence intervals.

*: $P<0.05$.

PAF-AH: platelet activating factor acetylhydrolase; *TMD*: traditional Mediterranean diet; *TMD-Nuts*: traditional Mediterranean diet enriched with mixed nuts; *TMD-VOO*: traditional Mediterranean diet enriched with virgin olive oil.

Figure 2. Associations between changes in food group intakes (1 serving) and 1-year changes in thrombosis biomarkers



*: $P<0.05$; **: $P<0.01$.

PAF-AH: platelet activating factor acetylhydrolase; *PAI-1*: plasminogen activator inhibitor-1.

Figure 3. Spearman's correlations among 1-year changes in thrombosis biomarkers.



Blue squares depict significant positive associations and red ones depict significant inverse correlations (P<0.0045).

HDL: high-density lipoproteins; *PAF-AH*: platelet activating factor acetylhydrolase; *PAI-1*: plasminogen activator inhibitor-1.